Triptorelin is a luteinizing hormone releasing hormone (LHRH) agonist.

• Number 1 product of Ipsen
• Indications: advanced prostate cancer, endometriosis, precocious puberty, in-vitro fertilisation programs, uterine fibroids
• Licensees: Ipsen (Pamorelin® and Pamorelin® LA ), Watson (Trelstar® Depot & Trelstar® LA), Ferring (Decapeptyl® Depot) , Tecnofarma (Decapeptyl®), Aché (Neo-Decapeptyl ®), Rowfarma (Pamorelin®) and Sidus (Decapeptyl Retard®)
• Current licensee sales in excess of $400M

Decapeptyl®, Trelstar®  history

Licensed-in
In 1982 from Tulane University. It had previously been abandoned by several pharmaceutical companies.

Status at in-licensing
Late preclinical phase

• Developed and submitted a 1- and 3-month sustained release formulation in Europe and the United States
• First worldwide sustained release formulation of a luteinizing hormone releasing hormone (LHRH) agonist
• Developed a new salt, storage at room temperature, extended patent life
• continuous life cycle management (LCM) (6 month formulations, new injection devices, new indications and new territories)

Timeline
European approval obtained in 1986 within four years of in-licensing.

Selected Publications